PSY93 - COST EFFECTIVENESS OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE IN ADULT CMV-SEROPOSITIVE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT- AN ENGLISH PAYER PERSPECTIVE

Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.2668
https://www.valueinhealthjournal.com/article/S1098-3015(18)35970-9/fulltext
Title : PSY93 - COST EFFECTIVENESS OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE IN ADULT CMV-SEROPOSITIVE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT- AN ENGLISH PAYER PERSPECTIVE
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35970-9&doi=10.1016/j.jval.2018.09.2668
First page :
Section Title :
Open access? : No
Section Order : 2020
Categories :
Tags :
Regions :
ViH Article Tags :